Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses in French this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1).
David Henry, MD, of Pennsylvania Hospital, discusses the exciting developments in multiple myeloma treatment, including the three new drugs approved for the disease in November 2015.
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).
Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).
Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577). To see the French language version of this video, please click here.
Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).
